<DOC>
	<DOCNO>NCT02844491</DOCNO>
	<brief_summary>Cancer-specific splice variant gain significant interest generate neo-antigens , could target immune cell . CD20 , membrane antigen broadly express mature B cell lymphoma , subject alternative splicing name Delta-CD20 leading loss membrane expression splice isoform . The investigator group would determine 's possible , patient lymphoproliferative B , detect presence specific memory response delta-CD20 peptide . If memory response exists , confirm interest antigen target tumor immunotherapy .</brief_summary>
	<brief_title>Study T Specific Immune Response Against Delta-CD20 Peptide Hematological Malignancies B</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>For patient : â€¢Written informed consent For Cohort A : Patient hematological malignancy high grade phenotype B ( non Hodgkin 's lymphoma diffuse large cell ) low grade ( mantle cell lymphoma , follicular lymphoma , marginal zone lymphoma Waldenstrom disease ) , regardless initial extension stage . Histologically cytologically immunophenotypical confirm Patient candidate secondline therapy Firstline treatment rituximab For Cohort B : Absence prior treatment antiCD20 antibody Histologically cytologically immunophenotypical confirm For patient : Patient medical psychiatric condition disease , Patient guardianship , curatorship protection justice pregnant woman For Cohort A : Patient chronic lymphocytic leukemia Patient indolent lymphoma relapse 1 year treatment Rituximab Patient allogeneic hematopoietic cell Patient link lymphoproliferative syndrome congenital immunosuppression ( eg SCID , XLP ... ) acquire ( posttransplant lymphoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>